Contineum misses Phase 2 primary endpoint in MDD trial

Contineum Therapeutics announced that the MOONLIGHT-1 trial evaluating JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint for major depressive disorder, though the candidate was well-tolerated with no new safety signals.